Physician profile
Mark David Pell
NPI 1639433261
$2,057.90
in general payments reported to CMS, 2019-2025
30 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.72 · 2020: $231 · 2021: $412 · 2022: $447 · 2023: $292 · 2024: $410 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $566.57 | 2021-2025 | Stravix, Grafix, Grafix Pl |
| Stryker Corporation | $223.52 | 2020-2021 | |
| Aroa Biosurgery Incorporated | $176.56 | 2022-2025 | |
| Paragon 28, INC. | $153.48 | 2019-2024 | Gorilla, Portfolio |
| Integra Lifesciences Corporation | $113.99 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ibsa Pharma INC. | $104.53 | 2022-2024 | Tirosint, Licart, Licart |
| Horizon Therapeutics Plc | $96.17 | 2020 | |
| Corcept Therapeutics | $89.72 | 2021-2023 | Korlym |
| Novo Nordisk INC | $57.06 | 2020-2022 | |
| Acera Surgical, INC. | $46.41 | 2024 | Restrata Wound Matrix |
| Treace Medical Concepts, INC. | $45.10 | 2024 | |
| Depuy Synthes Sales INC. | $41.00 | 2019 | |
| Abbvie INC. | $39.79 | 2021 | |
| Merck Sharp & Dohme LLC | $28.13 | 2019 | |
| Kerecis Limited | $27.70 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $27.35 | 2020-2022 | |
| Biotissue Holdings INC. | $22.91 | 2024 | |
| Nevro Corp. | $20.26 | 2023 | Senza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.45 | 2021 | |
| Eisai INC. | $17.47 | 2022 | |
| Melinta Therapeutics, LLC | $16.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.90 | 2023 | Cycloset |
| Mannkind Corporation | $15.81 | 2022 | |
| Abbott Laboratories | $14.51 | 2023 | Freestyle Libre 3 |
| Allergan, INC. | $13.99 | 2020 | |
| Convatec INC. | $13.44 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.43 | 2022 | |
| Bioventus LLC | $13.43 | 2024 | Exogen Ultrasound Bone Healing System |
| Orthofix Medical, INC. | $12.54 | 2021 | |
| Alfasigma USA, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.